6月12日，康方生物盘中上涨3.13%，报89.8港元，成交额3.5亿港元。消息面上，公司于6月11日公告董事会批准动用最多2亿港元在公开市场回购股份，同时公司主席夏瑜博士及多位执行董事、首席财务官拟合计增持上限5000万港元，资金由个人自有资金出资。
背景上，康方生物自6月1日ASCO全体会议公布依沃西HARMONi-6研究OS阳性结果后持续回调，累计跌幅逾30%，股价逼近52周低位。董事会明确表示现行股价未能反映公司内在价值及业务前景，认为当前为购买良机。此外，中泰证券等多家机构近日维持买入评级，近90天目标均价约182.55港元，较当前股价溢价显著。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.